Merck/Pfizer up the pressure on BMS in first-line kidney cancerThe FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney Share XMerck/Pfizer up the pressure on BMS in first-line kidney cancerhttps://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
Gilead NASH drug fails late stage trialGilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a Share XGilead NASH drug fails late stage trialhttps://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/
Scotland says no to Yescarta, but backs KymriahScotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types Share XScotland says no to Yescarta, but backs Kymriahhttps://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/
UCB joins with UK charity to research new epilepsy drugsBelgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for Share XUCB joins with UK charity to research new epilepsy drugshttps://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/
Pharma companies clear the R&D decks in Q4The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as Share XPharma companies clear the R&D decks in Q4https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/
Alector kicks off biotech IPOs after US government shutdownThe 35-day US government shutdown has not just played havoc at government-run agencies – it has had a Share XAlector kicks off biotech IPOs after US government shutdownhttps://pharmaphorum.com/news/alector-kicks-off-biotech-ipos-after-us-government-shutdown/
Gene therapy biotech shares sink on inconclusive trial resultsShares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results Share XGene therapy biotech shares sink on inconclusive trial resultshttps://pharmaphorum.com/news/gene-therapy-biotech-shares-sink-on-inconclusive-trial-results/
AZ’s lung drug gets fast development in EU and USRegulators in the US and Europe have fast-tracked development of AstraZeneca’s MEDI8897, an antibody drug aimed at preventing Share XAZ’s lung drug gets fast development in EU and UShttps://pharmaphorum.com/news/us-and-eu-accelerate-medi8897/
Lilly scores with two Olumiant trials in atopic dermatitisEli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which Share XLilly scores with two Olumiant trials in atopic dermatitishttps://pharmaphorum.com/news/lilly-scores-with-two-olumiant-trials-in-atopic-dermatitis/
